Deoxycholic acid - Kythera Biopharmaceuticals

Drug Profile

Deoxycholic acid - Kythera Biopharmaceuticals

Alternative Names: ATX-101-Kythera; Belkyra; Kybella; Sodium deoxycholate; Sodium desoxycholate

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kythera Biopharmaceuticals
  • Developer Bayer Dermatology; Kythera Biopharmaceuticals
  • Class Choleretics; Cholic acids; Gallstone therapies; Small molecules
  • Mechanism of Action Cell membrane modulators; Membrane lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Subcutaneous fat disorders
  • No development reported Lipoma

Most Recent Events

  • 13 Oct 2016 Preregistration for Subcutaneous fat disorders in Slovakia, Slovenia, Portugal, Poland, Malta, Luxembourg, Greece, Finland, Czech Republic, Cyprus (SC)
  • 13 Oct 2016 Registered for Subcutaneous fat disorders in Australia (SC)
  • 13 Oct 2016 Registered for Subcutaneous fat disorders in Norway, Bulgaria, Romania, Latvia, Estonia, Lithuania, Austria, Hungary, Iceland, Sweden (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top